Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
News-Medical.Net on MSN4d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
"Heart attacks and strokes are among the most common ... Those in the medication group took a once-daily 14mg dose of oral ...
Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback